# Drug Therapy for Melanoma: Current Updates and Future Prospects

## TL;DR

This review discusses recent advances in melanoma drug therapy, including immunotherapy and targeted treatments, and highlights ongoing challenges and future directions for improving patient outcomes.

## Contribution

The paper provides a comprehensive overview of current and emerging melanoma therapies, emphasizing personalized treatment strategies and overcoming drug resistance.

## Key findings

- Immunotherapy has significantly improved long-term survival for advanced-stage melanoma patients.
- Combination therapies and personalized vaccines show promise but come with notable toxicities.
- Patient-specific factors like BRAF mutations and brain metastases influence treatment choices and outcomes.

## Abstract

Melanoma is an aggressive form of skin cancer that was previously challenging to treat once it spread to other parts of the body. Over the past decade, major advances in drug therapies have dramatically improved survival for many patients. In this review, we explain why new melanoma treatments are needed, we summarize the main types of modern therapies currently used in clinical practice, and we discuss promising new approaches under development. These include immune-based treatments which help the body recognize and attack cancer cells, targeted drugs that block specific genetic changes in tumors, and emerging strategies such as personalized vaccines and cell-based therapies. By outlining current treatment options, ongoing challenges such as drug resistance and side effects, and future research directions, we aim to help researchers and clinicians better understand how melanoma treatment is evolving and how these advances may continue to improve outcomes for patients.

Melanoma was once considered ‘incurable’; however, drug therapy for the condition has dramatically transformed with the advent of immune checkpoint inhibitors and molecular targeted therapies. In this review, we summarize the published literature on melanoma drug therapy, presenting the current landscape of melanoma treatments, and discuss potential future transformations in melanoma therapy. Although the prognosis of advanced-stage melanoma had been extremely poor in the past, new-age immunotherapy has made long-term survival possible. Several immunotherapies and their combinations, as well as personalized vaccines, cell therapies, and intratumoral agents, have been tested with success; however, adverse toxicities have also been detected. Therefore, patient selection and management are critical. Furthermore, new approaches to overcome the limitations of the current treatments are also being developed. To implement these therapies clinically, guideline-recommended treatment algorithms should be followed while optimizing the therapies by considering factors such as presence of BRAF mutations which may lead to treatment resistance, increased disease burden/progression rate, toxicity tolerance, and the presence of brain metastases. In practice, the choice of the initial therapy should depend on the patient, leading to personalized therapy and minimal adverse effects.